SHANGHAI – Another month, another announcement for Lee's Pharmaceuticals Ltd., of Hong Kong, as it has been slowly but surely building a successful biotech business and developing and commercializing products for the China market. Read More

TIANJIN, China – Among the country's plan to boost its biopharmaceutical sector, a focus on developing antibodies is likely to characterize the development of the industry over the next few years, said officials and executives during an annual gathering. Read More

HONG KONG – A joint effort by 3SBio Inc. and its new partner Selecta Biosciences Inc. could lead to better treatments for patients with refractory and tophaceous gout. The two companies will work together to combine two products developed independently into one drug that could be distributed globally. Read More

SHANGHAI – Newcomer Ark Biosciences Inc., of Shanghai, has announced its first deal with the acquisition of global rights to Roche AG's respiratory syncytial virus (RSV) drug candidate, AK0529. RSV is one of the most infectious human viruses and the number one cause of death and hospitalization for children younger than 5. There is currently no vaccine or therapeutic drug for RSV infection. Read More

TIANJIN, China – Although the future of stem cell technology is bright, the sector in China has suffered due to a lack of clear regulations, with the then-Ministry of Health suspending clinical research and application of stem cell technology in 2011. Read More

HONG KONG – After decades of trials, blind alleys and false starts, a vaccine for dengue is finally close to market, and patients in Asia may be among the first to benefit from it. Read More

HONG KONG – Just months before the launch of a vaccination campaign, Japan has approved an extended indication for Pfizer Inc.'s pneumococcal conjugate vaccine to cover the elderly. Read More

Wuxi Pharmatech Inc., of Shanghai, said its toxicology facility in Suzhou, China, recently passed a surveillance good laboratory practice inspection by the FDA with no major observations. This was the first such inspection in the facility's five years of operation. The inspection was extensive, lasting five days and included the review of numerous processes and the audit of four studies, the company said. Read More

SHANGHAI – Chia-Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), of Jiangsu, has taken steps to bring a biosimilar version of Pfizer Inc.'s Xyntha, a recombinant human coagulation factor VIII (rhFVIII), to the clinic and moves a step closer to providing a much-needed, affordable treatment for China's hemophilia A sufferers. Read More